Pliant Therapeutics Inc (NASDAQ: PLRX) on Monday, plunged -3.85% from the previous trading day, before settling in for the closing price of $1.3. Within the past 52 weeks, PLRX’s price has moved between $1.10 and $16.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -78.30%. The company achieved an average annual earnings per share of 28.84%. With a float of $54.04 million, this company’s outstanding shares have now reached $61.39 million.
Let’s determine the extent of company efficiency that accounts for 171 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Pliant Therapeutics Inc (PLRX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Pliant Therapeutics Inc is 11.97%, while institutional ownership is 86.96%. The most recent insider transaction that took place on Jan 17 ’25, was worth 587,150. In this transaction President and CEO of this company sold 52,419 shares at a rate of $11.20, taking the stock ownership to the 430,517 shares. Before that another transaction happened on Jan 17 ’25, when Company’s Chief Financial Officer sold 20,148 for $11.20, making the entire transaction worth $225,680. This insider now owns 262,608 shares in total.
Pliant Therapeutics Inc (PLRX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.48 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 28.84% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 31.14% during the next five years compared to -78.30% drop over the previous five years of trading.
Pliant Therapeutics Inc (NASDAQ: PLRX) Trading Performance Indicators
Pliant Therapeutics Inc (PLRX) is currently performing well based on its current performance indicators. A quick ratio of 11.03 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.61, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -1.91 in one year’s time.
Technical Analysis of Pliant Therapeutics Inc (PLRX)
Looking closely at Pliant Therapeutics Inc (NASDAQ: PLRX), its last 5-days average volume was 2.92 million, which is a jump from its year-to-date volume of 1.89 million. As of the previous 9 days, the stock’s Stochastic %D was 28.94%.
During the past 100 days, Pliant Therapeutics Inc’s (PLRX) raw stochastic average was set at 1.27%, which indicates a significant decrease from 4.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.29% in the past 14 days, which was lower than the 230.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4348, while its 200-day Moving Average is $7.5146. However, in the short run, Pliant Therapeutics Inc’s stock first resistance to watch stands at $1.3100. Second resistance stands at $1.3700. The third major resistance level sits at $1.4000. If the price goes on to break the first support level at $1.2200, it is likely to go to the next support level at $1.1900. Now, if the price goes above the second support level, the third support stands at $1.1300.
Pliant Therapeutics Inc (NASDAQ: PLRX) Key Stats
Market capitalization of the company is 76.73 million based on 61,386K outstanding shares. Right now, sales total 0 K and income totals -210,300 K. The company made 0 K in profit during its latest quarter, and -56,170 K in sales during its previous quarter.
